{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:32:03Z","timestamp":1773379923461,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.farma.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:49:18Z","timestamp":1754452158000},"page":"102-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose abiraterone acetate for the treatment of prostate cancer: An observational cohort study"],"prefix":"10.1016","volume":"50","author":[{"given":"Luis Angel","family":"Di-Giuseppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney Alexander","family":"Ramirez-Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano Daniel","family":"Aymar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Roberto","family":"Basbus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Adri\u00e1n","family":"Terrasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lourdes","family":"Posadas-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Andrea","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Buela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Cayol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2025.06.012_bb0005","article-title":"Cost-effectiveness analysis of triptorelin, goserelin, and leuprolide in the treatment of patients with metastatic prostate cancer: a societal perspective","volume":"42","author":"Rezaee","year":"2024","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"10.1016\/j.farma.2025.06.012_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.farma.2025.06.012_bb0015","first-page":"5","article-title":"Gu\u00eda para el diagn\u00f3stico y tratamiento del c\u00e1ncer de pr\u00f3stata","volume":"88","author":"Castro","year":"2023","journal-title":"Rev Argent Urol"},{"issue":"11","key":"10.1016\/j.farma.2025.06.012_bb0020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jjco\/hyy129","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study","volume":"48","author":"Suzuki","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.farma.2025.06.012_bb0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.farma.2025.06.012_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jval.2020.04.1838","article-title":"Cost-effectiveness assessment of monitoring abiraterone levels in metastatic castration-resistant prostate cancer patients","volume":"24","author":"Ten Ham","year":"2021","journal-title":"Value Health"},{"issue":"14","key":"10.1016\/j.farma.2025.06.012_bb0035","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer","volume":"36","author":"Szmulewitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.farma.2025.06.012_bb0040","first-page":"261","article-title":"Definici\u00f3n de medicamento de alto precio y muy alto precio para Argentina [Definition of high-priced and very high-priced drugs for Argentina]","volume":"85","author":"Donato","year":"2025","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.farma.2025.06.012_bb0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/GO.20.00140","article-title":"Potential cost savings with low-dose abiraterone in the United States","volume":"6","author":"Premnath","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"10.1016\/j.farma.2025.06.012_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.31557\/apjcb.2024.9.4.447-454","article-title":"Real-world clinical outcomes of low dose versus standard dose abiraterone in patients with metastatic castration-resistant prostate cancer: a prospective pragmatic study","volume":"9","author":"Razmjoo","year":"2024","journal-title":"Asian Pac J Cancer Biol"},{"issue":"6","key":"10.1016\/j.farma.2025.06.012_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102191","article-title":"Real-world efficacy and safety of low-dose abiraterone with food and standard-dose abiraterone in de Novo metastatic hormone-sensitive prostate cancer: a retrospective analysis","volume":"22","author":"Do","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.farma.2025.06.012_bb0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JGO.19.00341","article-title":"Low-dose abiraterone in metastatic prostate cancer: is it practice changing? Facts and facets","volume":"6","author":"Patel","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"12","key":"10.1016\/j.farma.2025.06.012_bb0065","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.farma.2025.06.012_bb0070","article-title":"A primer on RECIST 1.1 for oncologic imaging in clinical drug trials","volume":"3","author":"Ruchalski","year":"2021","journal-title":"Radiol Imag Cancer"},{"key":"10.1016\/j.farma.2025.06.012_bb0075","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). [cited 2025 May 19]. Last updated: 2025 Feb 01. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"6","key":"10.1016\/j.farma.2025.06.012_bb0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.farma.2025.06.012_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.farma.2025.06.012_bb0090","first-page":"3097","article-title":"Low-dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of \u226585-year-old patients with advanced castrate-resistant prostate cancer","volume":"35","author":"Petrioli","year":"2015","journal-title":"Anticancer Res"},{"issue":"15_suppl","key":"10.1016\/j.farma.2025.06.012_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e17571","article-title":"The study of the treatment efficacy in metastatic castration-resistant prostate cancer of low dose abiraterone with food","volume":"38","author":"Makphanchareonkit","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.farma.2025.06.012_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19315","article-title":"Real-world evidence: a retrospective-cohort study of castration-resistant advanced prostate cancer (CRAPC) patients treated with abiraterone 1.000 mg or 250 mg","volume":"38","author":"Smolje","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.farma.2025.06.012_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.prnil.2021.10.001","article-title":"Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer","volume":"10","author":"Yamada","year":"2022","journal-title":"Prostate Int"},{"issue":"6","key":"10.1016\/j.farma.2025.06.012_bb0110","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00280-019-03952-w","article-title":"A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics","volume":"84","author":"Lubberman","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15_suppl","key":"10.1016\/j.farma.2025.06.012_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e17563","article-title":"Real-world outcome with abiraterone low-dose plus prednisone in patients with mCRPC in a Brazilian Public Cancer Center","volume":"38","author":"Zucca","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:38:18Z","timestamp":1773351498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1130634325001023"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.06.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose abiraterone acetate for the treatment of prostate cancer: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}